Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 1 - Drugs for disorders of the alimentary tract or the digestive system
Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798)
03/2003
03/06/2003WO2003018836A2 Model of autoimmune disease and methods for identifying agents against autoimmune disease
03/06/2003WO2003018823A1 Obesity related genes expressed at least in the hypotalamus, liver or pancreas
03/06/2003WO2003018793A1 Novel gene having guanine nucleotide exchange factor-like sequence
03/06/2003WO2003018756A2 Methods for preparing purified prostaglandin e synthase
03/06/2003WO2003018619A2 Antimicrobial and anti-inflammatory peptides
03/06/2003WO2003018585A1 Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
03/06/2003WO2003018582A1 Novel imidazopyridine compounds with therapeutic effect
03/06/2003WO2003018579A1 Alkyne-aryl phosphodiesterase-4 inhibitors
03/06/2003WO2003018576A1 New piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity
03/06/2003WO2003018556A1 Piperidine derivatives useful as modulators of chemokine receptor activity
03/06/2003WO2003018538A1 Novel diarylalkene derivatives and novel diarylalkane derivatives
03/06/2003WO2003018535A2 Novel aminobenzoephenones
03/06/2003WO2003018516A2 Glucagon-like peptide-1 analogs
03/06/2003WO2003018515A2 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
03/06/2003WO2003018134A2 Bioadhesive compositions and methods for enhanced mucosal drug absorption
03/06/2003WO2003018069A1 Preparation and diabetic use of gibberellins
03/06/2003WO2003018054A1 Helicobacter pylori vaccination
03/06/2003WO2003018049A2 Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection
03/06/2003WO2003018044A1 New drug
03/06/2003WO2003018034A1 Antacid and laxative tablets
03/06/2003WO2003018020A1 Jnk inhibitors
03/06/2003WO2003018012A1 Preventive agent/remedial agent for constipation predominant ibs
03/06/2003WO2003017983A1 A new extended release oral dosage form
03/06/2003WO2003017982A1 A new extended release oral dosage form
03/06/2003WO2003017960A1 Oral rinse for treatment or prevention of bacterial and fungal infection
03/06/2003WO2003017946A2 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/06/2003WO2003017940A2 Pulsatile release compositions and methods for enhanced gastrointestinal drug absorption
03/06/2003WO2003017935A2 Human antibodies specific for interleukin 15 (il-15)
03/06/2003WO2003002131B1 Strain of micro-organism lactobacillus fermentum me-3 as novel anti-microbial and antioxidative probiotic
03/06/2003WO2002096367A3 Targeted multivalent macromolecules
03/06/2003WO2002086069A3 Secreted proteins
03/06/2003WO2002085945A3 Vhh single heavy chain antibody and a method for its preparation in a mammal
03/06/2003WO2002072570A3 Non-imidazole compounds as histamine h3 antagonists
03/06/2003WO2002066516A3 Antibodies that bind both bcma and taci
03/06/2003WO2002066511A3 Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
03/06/2003WO2002064092A3 Method for evaluating therapeutic efficacy
03/06/2003WO2002058692A9 Halogenated composition, method for preparing same and uses thereof
03/06/2003WO2002043753A8 Remedies for chronic hepatitis b
03/06/2003WO2002041837A3 Treatment of mucositis
03/06/2003WO2002034726A9 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
03/06/2003WO2002028481A3 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
03/06/2003WO2002020516A1 Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient
03/06/2003WO2002009714A9 Compositions and methods for the treatment of anorectal disorders
03/06/2003WO2002009537A3 Alpha- (1, 4) linked glucose polymers containing oral compositions to alleviate or prevent tooth damage
03/06/2003WO2001092304A3 Transporters and ion channels
03/06/2003US20030046718 Administering compounds having an effect on cardiac fibrosis, myocardial infarction, defects in electrical conductance, atherosclerosis, unstable plaque, and stroke in an animal which does not express an active SR-BI, and an apolipoprotein
03/06/2003US20030045724 Benzimidazole compound crystal
03/06/2003US20030045574 Such as alpha-phenyl-N-(7-tert-butoxycarbonylamino-3,5-dimethyladamantane)nitrone for treatment of neurological/ inflammatory diorders, and aging, which result from the overproduction of nitric oxide
03/06/2003US20030045565 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
03/06/2003US20030045554 Such as 1-(2-thien-2'-yl- 2-oxoethyl)-3-((3-phenylmethyl) pyrazol-5-yl)pyridinium bromide for treating diseases caused by the accumulation of AGE (Advanced Glycation Endproducts); antidiabetic/ antiaging agents
03/06/2003US20030045552 Isoindole-imide compounds, compositions, and uses thereof
03/06/2003US20030045546 Anticancer agents
03/06/2003US20030045544 Bactericides for the oral region of animals using 3-carboxy-4-oxo quinoline or 1,8-naphthyridine derivatives or 1-cyclopropyl-3-carboyx-4-oxo quinolizine derivatives
03/06/2003US20030045540 Nicotinic acetylcholine receptors antagonists; central nervous system disorder treatments
03/06/2003US20030045530 Administering a piperazine or piperidine coupled through a linker to a benzhydril
03/06/2003US20030045527 Treating central nervous system or gastrointestinal disorders
03/06/2003US20030045519 Treating allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion)
03/06/2003US20030045517 Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
03/06/2003US20030045516 Chemokine receptor antagonists and methods of use therefor
03/06/2003US20030045508 Phosphoramidates
03/06/2003US20030045490 Therapeutic antisense phosphodiesterase inhibitors
03/06/2003US20030044898 Nucleotide sequences coding polypeptide for use in the treatment of asthma, parkinson's, heart defects, hypotension, urogenital and bone disorders
03/06/2003US20030044893 Nectin polypeptides, polynucleotides, methods of making and use thereof
03/06/2003US20030044892 Novel human G-protein coupled receptor, HGPRBMY6, expressed highly in small intestine
03/06/2003US20030044476 Use for its anti-elastase and anti-inflammatory activity on human gums; chewing gum or gel for treating gingivitis
03/06/2003US20030044464 Sustained-release, oral pharamaceutical forms of formulation
03/06/2003US20030044397 In digestable carrier; therapy for liver disorders
03/06/2003US20030044386 Genetic engineering; nucleic acid coding cytokines
03/06/2003US20030044356 Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
03/06/2003CA2458854A1 Helicobacter pylori vaccination
03/06/2003CA2458849A1 Obesity related genes expressed at least in the hypothalamus, liver or pancreas
03/06/2003CA2458565A1 New angiogenesis inhibitors based on soluble cd44 receptor hyaluronic acid binding domain
03/06/2003CA2458443A1 Bioadhesive compositions and methods for enhanced mucosal drug absorption
03/06/2003CA2458375A1 Substituted-heteroaryl-7-aza¬2.2.1|bicycloheptanes for the treatment of disease
03/06/2003CA2458371A1 Glucagon-like peptide-1 analogs
03/06/2003CA2458219A1 Oral rinse for treatment or prevention of bacterial and fungal infection
03/06/2003CA2458131A1 Jnk activation inhibitor
03/06/2003CA2457885A1 Antimicrobial and anti-inflammatory peptides
03/06/2003CA2457532A1 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/06/2003CA2457341A1 A new extended release oral dosage form
03/06/2003CA2457339A1 A new extended release oral dosage form
03/06/2003CA2456350A1 Novel imidazopyridine compounds with therapeutic effect
03/06/2003CA2449515A1 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
03/06/2003CA2421499A1 Novel crystals of 1,3,4-oxadiazole derivative, process for producing the same and pharmaceutical agent containing the same as active ingredient
03/05/2003WO2002020566A2 NOVEL MMP-2 DERIVATIVES FOR USE AS INHIBITORS OF INTEGRIN αVβ¿3?
03/05/2003EP1288299A2 TRNA synthetase
03/05/2003EP1288228A1 BMP-2-derived peptides having osteogenetic activity and osteogenetic accelerator containing the same
03/05/2003EP1288224A1 Therapeutic peptide derivatives
03/05/2003EP1288223A1 Therapeutic peptide derivatives
03/05/2003EP1288222A1 Peptidic compounds selectively binding to P-selectin
03/05/2003EP1288216A1 Tricyclic quinazolinediones
03/05/2003EP1288206A1 Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
03/05/2003EP1288205A1 Novel phenylalanine derivatives
03/05/2003EP1287822A2 Mesalazine controlled release oral pharmaceutical compositions
03/05/2003EP1287130A2 Mammalian cytokine receptor subunit proteins, related reagents and methods
03/05/2003EP1287035A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
03/05/2003EP1287020A2 Cancer diagnosis and assays for screening anti-cancer agents
03/05/2003EP1287019A1 Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors
03/05/2003EP1286999A1 PYRANO[2,3-c]IMIDAZO[1,2-a]PYRIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
03/05/2003EP1286997A1 6-phenylpyrrolopyrimidinedione derivatives
1 ... 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 ... 1258